Incidence of Venous Thromboembolism following Knee Arthroscopy: Effectiveness of a Risk-Based Stratified Chemoprophylaxis Protocol

Abstract

The incidence of symptomatic venous thromboembolism (VTE) has been reported in up to 10.9% of patients undergoing knee arthroscopy without chemoprohylaxis. The purpose of this study was to evaluate the effectiveness of a chemoprophylaxis protocol in patients undergoing knee arthroscopy. A retrospective review of prospectively enrolled patients in a new institutional VTE prophylaxis protocol identified all patients undergoing knee arthroscopy during a 5-year period. This risk-based chemoprophylaxis protocol was instituted based on the Caprini model: patients at more than minimal risk were prescribed enoxaparin 40 mg daily for 3 weeks, while all others were instructed to take aspirin 325 mg twice daily. The primary outcome measure was incidence of VTE within 60 days postoperatively. Demographic characteristics and other risk factors for VTE were also recorded, as well as any postoperative complications. Among the 1,276 knee arthroscopies, there were 26 VTE events (2.0%), including 23 with deep vein thrombosis (DVT), two pulmonary emboli (PE), and one patient with both DVT and PE. There were no deaths or complications requiring hospitalization or reoperation. The VTE diagnosis occurred at, on average, 9 days postoperatively. Patients in the high-risk group treated with enoxaparin had a lower VTE incidence (1.49%) than those instructed to take aspirin (2.0%); p = 0.75. Those undergoing an anterior cruciate ligament (ACL) reconstruction had the highest VTE incidence (2.87%). This study found that a chemoprophylaxis protocol with preferential use of aspirin or low–molecular weight heparin based on risk factors reduced the VTE incidence below to 2.0%, which is lower than most historical controls.

Keywords

knee - arthroscopy - VTE - DVT - prophylaxis

Note

Research was performed at the Milton S. Hershey Medical Center, Hershey, PA.

Conflict of Interest

None declared.

Publikationsverlauf

Eingereicht: 23. Januar 2020

Angenommen: 25. Juni 2020

Artikel online veröffentlicht:
31. August 2020

• References

• 1 Kaye ID, Patel DN, Strauss EJ. et al. Prevention of venous thromboembolism after arthroscopic knee surgery in low-risk population with use of aspirin: a randomized trial. Bull Hosp Jt Dis (2013) 2015; 73 (04) 243-248
• 2 Krych AJ, Sousa PL, Morgan JA, Levy BA, Stuart MJ, Dahm DL. Incidence and risk factor analysis of symptomatic venous thromboembolism after knee arthroscopy. Arthroscopy 2015; 31 (11) 2112-2118
• 3 Sun Y, Chen D, Xu Z. et al. Incidence of symptomatic and asymptomatic venous thromboembolism after elective knee arthroscopic surgery: a retrospective study with routinely applied venography. Arthroscopy 2014; 30 (07) 818-822
• 4 Struijk-Mulder MC, Ettema HB, Verheyen CC, Büller HR. Deep vein thrombosis after arthroscopic anterior cruciate ligament reconstruction: a prospective cohort study of 100 patients. Arthroscopy 2013; 29 (07) 1211-1216
• 5 Maletis GB, Inacio MC, Reynolds S, Funahashi TT. Incidence of symptomatic venous thromboembolism after elective knee arthroscopy. J Bone Joint Surg Am 2012; 94 (08) 714-720
• 6 Hoppener MR, Ettema HB, Henny CP, Verheyen CC, Büller HB. Symptomatic deep vein thrombosis and immobilization after day-care arthroscopy of the knee. J Thromb Haemost 2005; 3 (01) 185-187
• 7 Delis KT, Hunt N, Strachan RK, Nicolaides AN. Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy. Thromb Haemost 2001; 86 (03) 817-821
• 8 Jaureguito JW, Greenwald AE, Wilcox JF, Paulos LE, Rosenberg TD. The incidence of deep venous thrombosis after arthroscopic knee surgery. Am J Sports Med 1999; 27 (06) 707-710
• 9 Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998; 158 (01) 47-50
• 10 Cullison TR, Muldoon MP, Gorman JD, Goff WB. The incidence of deep venous thrombosis in anterior cruciate ligament reconstruction. Arthroscopy 1996; 12 (06) 657-659
• 11 Williams Jr. JS, Hulstyn MJ, Fadale PD. et al. Incidence of deep vein thrombosis after arthroscopic knee surgery: a prospective study. Arthroscopy 1995; 11 (06) 701-705
• 12 Levi M. Low-molecular-weight heparin for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy. ACP J Club 2008; 149 (06) 10
• 13 Camporese G, Bernardi E, Prandoni P. et al; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 2008; 149 (02) 73-82
• 14 Muñoa L, González AB, Díaz de Rada P, Valentí A, Valentí JR. Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy. Musculoskelet Surg 2014; 98 (01) 21-25
• 15 Marlovits S, Striessnig G, Schuster R. et al. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study. Arthroscopy 2007; 23 (07) 696-702
• 16 Michot M, Conen D, Holtz D. et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low--molecular weight heparin. Arthroscopy 2002; 18 (03) 257-263
• 17 Wirth T, Schneider B, Misselwitz F. et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. Arthroscopy 2001; 17 (04) 393-399
• 18 Schippinger G, Wirnsberger GH, Obernosterer A, Babinski K. Thromboembolic complications after arthroscopic knee surgery. Incidence and risk factors in 101 patients. Acta Orthop Scand 1998; 69 (02) 144-146
• 19 Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S. Meta-Embol Group. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. Arthroscopy 2014; 30 (08) 987-996
• 20 Ramos J, Perrotta C, Badariotti G, Berenstein G. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev 2008; (04) CD005259
• 21 Falck-Ytter Y, Francis CW, Johanson NA. et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e278S-e325S
• 22 Sobieraj DM, Coleman CI, Tongbram V. et al; Agency for Health Care Research and Quality. Venous thromboembolism prophylaxis in orthopedic surgery: comparative effectiveness review no. 49. Available at: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/blood-clots-hip-knee-surgery_research.pdf . Accessed July 10, 2020
• 23 Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17 (Suppl. 03) 304-312
• 24 Jameson SS, Dowen D, James P, Serrano-Pedraza I, Reed MR, Deehan DJ. The burden of arthroscopy of the knee: a contemporary analysis of data from the English NHS. J Bone Joint Surg Br 2011; 93 (10) 1327-1333
• 25 Kwong L, Bookhard B, Mody S. Economic model comparing rivaroxaban and enoxaparin for post-orthopedic VTE prophylaxis. Am J Pharm Benefits 2013; 5 (03) 106-110
• 26 Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med 2014; 9 (09) 579-585